DermTech – Consensus Indicates Potential -29.0% Downside

Broker Ratings

DermTech with ticker code (DMTK) now have 4 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 79 and 34 calculating the average target price we see 53.75. Given that the stocks previous close was at 75.73 this would indicate that there is a downside of -29.0%. The 50 day moving average now sits at 51.51 while the 200 day moving average is 22.88. The company has a market cap of $1,809m. Find out more information at:

DermTech, a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company is also developing non-melanoma skin cancer diagnostic and non-melanoma skin cancer risk assessment products. The company sells its products primarily to pathology and oncology practitioners. DermTech is headquartered in La Jolla, California.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on reddit

AIM All Share Index